The firm filed for Chapter 11 protection on Thursday and is seeking to sell its assets after facing turmoil in recent years.

April's clearances included respiratory disease assays, a Gram-negative infection test, and assays to aid the diagnosis and monitoring of thyroid disease.

The company has received a commitment of up to $12.5 million in a multi-draw DIP financing facility to provide funding during the proceeding.

NEW YORK — Exagen, a developer of autoimmune testing technologies, said on Thursday it expects to raise around $17.6 million through a public offering of its common stock.